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Summary points 
Trigeminal neuralgia is a severe, unilateral, episodic pain of the face that is provoked by light 
touch; it should be differentiated from dental causes of pain 
Magnetic resonance imaging (MRI) can distinguish between patients having secondary 
trigeminal neuralgia related to tumours and that related to multiple sclerosis 
The first line drug for treatment is either carbamazepine or oxcarbazepine, and doses should 
be slowly escalated. Neurosurgical options should be discussed at an early stage but surgery 
may not be required until quality of life is compromised 
Microvascular decompression is a major neurosurgical procedure that provides the longest 
period of pain relief and aims to preserve function of the nerve 
Percutaneous, palliative destructive procedures and stereotactic radiosurgery can provide 
temporary relief, but at the risk of facial numbness, which increases with repetition of the 
procedure 
 
Trigeminal neuralgia is a rare, episodic facial pain that is unilateral, electric shock-like, 
and provoked by light touch. At first, it is often mistaken as a tooth problem owing to its 
presentation in the two lower branches of the trigeminal nerve. Patients may undergo 
unnecessary—and sometimes irreversible—dental treatment before the condition is 
recognised. Initially, a small dose of an antiepileptic drug (such as carbamazepine) rather 
than any analgesic drug can provide excellent pain relief. However, up to 10% of patients 
will not respond to antiepileptic drugs,[1] and in rare instances trigeminal neuralgia can be 
secondary to a brain tumour, multiple sclerosis, or vascular anomalies, which will only be 
identified on neuroimaging.[2] If quality of life becomes impaired and symptoms are 
uncontrolled with drug treatment, patients should be referred to a neurosurgeon for 
consideration of surgical management. Studies in Europe have shown that trigeminal 
neuralgia results in considerable interference with activities of daily living that is comparable 
to other neuropathic pain conditions,[3] and could lead to suicide.[4] This review aims to 
highlight the key features of trigeminal neuralgia and familiarise readers with both the 
 medical and surgical management of this condition, which remains based on limited evidence 
and expert opinion. 
 
Sources and selection criteria 
We used Medline and Embase and the search terms “trigeminal neuralgia” and “tic 
doloureux.” One author (JZ) has done Cochrane reviews on both medical and surgical 
outcomes for trigeminal neuralgia, and the search strategy is shown in those publications. We 
searched the Cochrane Neuromuscular Disease Group specialised register, Cochrane Library, 
Medline, and Embase using the search terms “trigeminal neuralgia/facial neuralgia/tic 
douloureux,” “tic doloureux,” “tic doloreux,” or “tic douloreux” with no language exclusion. 
Clinical knowledge summaries and international guidelines for trigeminal neuralgia were 
published in 2008, and the search strategy can be found on www.aan.com. We also used our 
own extensive archives of references. [A: Please check edits in this box] 
 
How common is trigeminal neuralgia? 
Trigeminal neuralgia is rare, and hence it is difficult to obtain high quality epidemiological 
data. Data from the United States and validated in the 1990s provided a crude annual 
incidence of 5.7 per 100<thin>000 women and 2.5 per 100<thin>000 men.[5] Peak incidence 
lies between age 50 and 60 years, with prevalence increasing with age. A general practice 
based survey in London of neurological diseases showed an incidence of 8 (95% confidence 
interval 4 to 13) per 10<thin>000 people per year and a lifetime prevalence of 0.7 (0.4 to 1) 
per 100,000 persons per annum [A: units? People per year?].[6] Subsequent studies 
examining general practice databases reported an incidence of 27 per 100<thin>000 person 
years in the United Kingdom,[7] and this figure was also noted in Holland. However, when 
trained specialists checked the data in Holland, the number fell to 12.6 per 100<thin>000 
person years.[8] A community based study in Germany using face to face interviews with 
trained neurologists reported a lifetime prevalence of 0.3%.[9] 
Who are most at risk of having trigeminal neuralgia? 
Data from the US have found that women were more at risk than men  of trigeminal 
neuralgia [A: more at risk than men?], but the association was not as strong if correction 
was made for women living longer than men [A: than men?].[5] The strongest association of 
having trigeminal neuralgia is with multiple sclerosis, which has been seen in both 
epidemiological data and in data for multiple sclerosis.[10] There could also be an association 
 with hypertension[5] and stroke,[11] but this could be due to chance because the 
epidemiology is similar between hypertension and other degenerative diseases. 
What is the underlying pathophysiology of trigeminal neuralgia? 
Large surgical series from many different centres  [A: facial sites?] have confirmed that 
microvascular decompression of the trigeminal nerve root is the most effective and durable 
treatment for trigeminal neuralgia. Strong empirical evidence indicates that vascular 
compression of the trigeminal nerve root is associated with trigeminal neuralgia in about 95% 
of patients.[12] However, the exact pathophysiology of how vascular compression leads to 
trigeminal neuralgia remains speculative. Popular hypotheses include a combination of 
central demyelination of the nerve root entry zone [A: We avoid overly long noun clusters] 
and reinforcing electrical excitability (the ignition hypothesis).[13-17] Recent studies suggest 
that this demyelination then leads to an impairment of the nociceptive system. Those patients 
with more background pain seem to have a loss of central inhibition of the nociceptive 
system[18]; even after successful surgery, some form of abnormality of somatosensory 
function remains.[19] Other factors including predisposing biology on a genetic basis are 
likely to be important because although rare, familial clusters do exist.[20] 
The remaining small subset of trigeminal neuralgia cases are associated with multiple 
sclerosis plaques or lacunar infarctions within the brain stem trigeminal system or 
cerebellopontine mass lesions.[21] [22] Demyelinating multiple sclerosis plaques have been 
reported involving brain stem trigeminal nuclei. However, in a study of consecutive patients 
with multiple sclerosis, MRI showed that the only lesion localisation common to all patients 
was the intrapontine course of fibres in the fascicular trigeminal nerve root,[23] lending 
further support to the role of demyelination at the central nerve root in trigeminal neuralgia. 
How is trigeminal neuralgia diagnosed? 
The box shows the key clinical features and red flags of trigeminal neuralgia. The 
diagnosis of trigeminal neuralgia and other episodic, unilateral neuralgiform pain is based 
nearly entirely on the history. However, the diagnostic criteria have not been validated by 
case-control studies and remain based on expert consensus, mainly from headache 
neurologists and epidemiological studies from the 1990s.[24] Trigeminal neuralgia often 
starts suddenly with a memorable onset. The periods of remission tend to get shorter with 
time and the attacks of pain often get longer; 65% of patients newly diagnosed with 
trigeminal neuralgia will have a second episode within five years, and 77% within 10 
years.[5] Fifty per cent of patients will have remissions of at least six months’ duration. 
Patients can have as few as three or four attacks a day [A: Is this a usual/average number?], 
 but they could have as many as 70 per day. At times the attacks of pain come so quickly that 
it is impossible to determine whether there is a gap between each attack. There is often a 
refractory period when the pain cannot be triggered. Pain can occur at night in a third of 
patients. It is unusual to have trigeminal neuralgia in the first ophthalmic division of the 
trigeminal nerve  only [A: Please explain “first division” for generalists].  
 
Box: Diagnostic criteria for trigeminal neuralgia and red flags 
Site  
Pain is [A: mainly?] unilateral in the distribution of the trigeminal nerve, bilateral in only 3% 
of patients, and rarely is the pain active on both sides at the same time [A: What is rarely at 
the same time?] 
Periodicity 
Episodic and sudden onset of pain, lasting a few seconds to minutes and stopping suddenly, 
with many attacks a day. There is a refractory period between each attack. Pain might then go 
into remission for weeks or months; pain-free intervals gradually shorten between episodes 
Character  
Electric shock-like, sharp, shooting 
Severity 
Very severe attacks, but attacks can get milder when patients are given drug treatment 
Factors affecting pain 
Can be provoked by light touch to the face, eating, cold winds, or vibrations 
Associated factors 
Rarely associated with history of other chronic pain or migraine. Some forms have more 
continued aching background pain after main attack. Rarely associated with autonomic 
features 
Red flags  
Sensory changes, deafness or other ear problems, difficult achieve pain control [A: To 
control what – facial movement?], poor response to carbamazepine, history of any skin 
lesions or oral lesions that could lead to perineural spread, ophthalmic division only or 
bilateral as suggestive of benign or malignant lesions  or multiple sclerosis [A: Please 
explain further], age of onset under 40 years, optic neuritis, family history of multiple 
sclerosis 
 
[A: We avoid overly long paragraphs] Some patients continue to have a background 
pain of lower intensity for 50% of the time. This condition has variously been called atypical 
trigeminal neuralgia, type 2[25] or—in the new International Classification for Headache 
Disorders—trigeminal neuralgia with concomitant persistent facial pain.[26] Some patients 
might also have autonomic features such as conjunctival injection, lacrimation, nasal 
congestion or rhinorrhoea, eye lid oedema, ptosis, or facial sweating.[26] In the presence of 
autonomic symptoms, it can be difficult to determine whether this is still trigeminal neuralgia 
or a variant known as short unilateral neuralgiform pain with autonomic symptoms (SUNA)  
 or short unilateral neuralgiform pain with conjunctival injection and lacrimation (SUNCT) . 
A retrospective study of patients who had undergone a microvascular decompression 
indicated that up to 67% reported one autonomic symptom and 14% had four or more, and 
that those with autonomic features were more likely to have a  [A: please define “these” -  
these percentages poorer response to surgery.[27] 
It is important to carefully examine the face and oral cavity, including an examination of 
the cranial nerves, because any abnormalities could indicate alternative [A: suggest using the 
term “alternative” as TN is also symptomatic] causes that would necessitate referral to a 
specialist. 
What investigations should be done? 
Trigeminal neuralgia itself is a purely clinical diagnosis. However, investigations could be 
required especially if red flags are noted (box) and the indications for them are based on case 
reports. These investigations are targeted towards identifying other craniofacial pain 
syndromes within a differential diagnosis of trigeminal neuralgia, identifying non-vascular 
compressive causes of trigeminal neuralgia, and obtaining baseline laboratory test values to 
assist with toxicity monitoring before starting pharmacological treatment. 
Patients’ self assessment tools could develop in time to the point when they allow for a 
sensitive and specific diagnosis of trigeminal neuralgia, but evidence so far is sparse. In small 
studies of patients with trigeminal neuralgia or atypical facial pain, the McGill Pain 
questionnaire (a general tool for use in all pain conditions) was able to predict the correct 
diagnosis in 90% of the patients.[28] [29] In another study, an extended version of the Brief 
Pain  Inventory identified the difference in effect on daily living between 114 patients with 
classic trigeminal neuralgia and 42 patients with atypical trigeminal neuralgia.[30] Both of 
these tools have yet to be externally validated in a larger series of patients with trigeminal 
neuralgia. 
Imaging 
The most useful investigation is a MRI scan of the brain with and without contrast, which 
is used to rule out other potential causes of pain if the diagnosis is not clear cut or if red flags 
are present [A: edit OK?].[31] [32] MRI is very sensitive in identifying the following 
features: 
 Sinusitis 
 Extracranial masses along the course of the trigeminal nerve 
 Pathological enhancement of the trigeminal nerve that could indicate perineural 
spread of malignancy 
  Cavernous sinus masses 
 Demyelination plaques that might indicate multiple sclerosis 
 Intrinsic brain lesions in the thalamus or trigeminal brain stem pathways such as 
lacunar infarctions 
 Cerebellopontine angle mass lesions such as tumour, epidermoid, dermoid, or 
arachnoid cyst, aneurysm, or arteriovenous malformation. 
MRI is the most sensitive screening and diagnostic test available for detecting multiple 
sclerosis and has the highest positive predictive value.[33] [34] Although rare, brain tumours 
can be associated with trigeminal neuralgia.[2] [35] Posterior fossa tumours are the tumours 
most likely to be associated with typical trigeminal neuralgia pain characteristics, and are 
most commonly vestibular schwannomas, meningiomas, or epidermoid cysts.[35] It is 
tempting to order an MRI scan to assess the trigeminal for vascular compression, and in our 
experience, it is sometimes requested by patients once they have been diagnosed with 
trigeminal neuralgia and have done some research on the subject. MRI can detect vascular 
contact with the trigeminal nerve; however, this contact is best seen with specialised T2 and 
T1 volumetric acquisition techniques with fine slicing in all three planes (fig 1[f1]). 
Figure -  zakj014776.f1 
Fig 1 MRI of the posterior fossa of the brain showing neurovascular compression. Sequential, 
0.8 mm, fine cut axial images from a volumetric T2 MRI acquisition on a patient with right 
sided trigeminal neuralgia. Caudal (A) and rostral (B) axial images shown. Origin of the 
trigeminal nerve from the brainstem on both sides is indicated by small arrows positioned 
along the course of the nerve. Inferior and lateral compression of the right trigeminal nerve 
route by a flow void representing the superior cerebellar artery is indicated by large arrows 
positioned perpendicular to the nerve course. The trigeminal nerve root is not only contacted 
but also displaced medially in its cisternal course by the superior cerebellar artery (B) 
These techniques are expensive and  not usually included as standard MRI head protocol 
[A: OK as edited?], and will only be available in specialist settings. In addition, because the 
vessels in question are normal blood vessels and vascular contact with cranial nerves is a 
normal variant [A: is it better to say that this is a variant rather than a condition if it is 
classed as normal?] found in many patients without trigeminal neuralgia,  an image showing 
vascular contact could be read as “normal” by the radiologist reading the study. A 
multidisciplinary evidence based review of the published literature by the American 
Academy of Neurology and the European Federation of Neurological Societies concluded 
that MRI is currently too insensitive for detecting vascular compression of the trigeminal 
nerve to recommend routine use.[31] [32] Some small studies with more sophisticated 
technology have suggested improved correlations but these technologies  [A: these 
technologies?] are not available routinely at present.[36] However, more sophisticated 
 techniques have been used recently, as reported in small series, which have shown actual 
changes in the trigeminal nerve.[37] [38] 
Biochemical investigations 
Depending on the drugs chosen to treat trigeminal neuralgia, particularly among 
antiepileptic drugs, issues related to reductions in white blood cell count, elevation in liver 
transaminases, and hyponatraemia are well documented. Thus, depending on the treatment 
planned, a complete blood count at baseline with differential [A: Correct as edited?], serum 
electrolytes, and liver function tests are needed to monitor for potential drug toxicity over 
time. Regular blood test monitoring is not recommended unless there is a clinical indication. 
For patients taking enzyme inducing drugs, the National Institute for Health and Care 
Excellence (NICE) recommends a full blood count, measurements of electrolytes, liver 
enzymes, and vitamin D levels, and other tests of bone metabolism (for example, serum 
calcium and alkaline phosphatase) every two to five years.[39] 
What are the medical options for treatment? 
All drugs currently used to treat trigeminal neuralgia were initially developed for other 
indications, principally for epilepsy. Only a handful of small randomised controlled trials 
have investigated drug treatments for trigeminal neuralgia [A: Correct?], many of which are 
old and have methodological flaws. International guidelines,[31] [32] Cochrane systematic 
reviews,[40-42] and Clinical Evidence[43] have highlighted the key treatments (table[t1] [A: 
Box 2 converted to a table, as it has more than 1 column]).  
Table -  zak014776.t1 
In the UK, the only drug licensed specifically for trigeminal neuralgia is carbamazepine, 
but drugs licensed for use in neuropathic pain are often used (trigeminal neuralgia is 
considered a neuropathic condition). However, updated NICE guidelines[44] for management 
of neuropathic pain state that in primary care only, carbamazepine should be used and if it 
fails patients should be referred for specialist care. The guidelines specifically exclude use of 
other neuropathic drugs for trigeminal neuralgia in primary care. All the drugs should be 
started at low doses and gradually escalated every three to seven days to determine the best 
pain control with lowest side effects. Careful monitoring is needed initially and if drug doses 
become high.  
The preferred drug remains to be carbamazepine (based on four small randomised 
controlled trials of poor quality), which provides initially 100% pain relief in 70% of 
patients.[40] However, many patients will have side effects, mainly affecting the central 
nervous system—such as tiredness and poor concentration—and there is a high risk of drug 
 interactions. The second drug of choice is oxcarbazepine, a keto derivative of carbamazepine 
that has shown similar efficacy to carbamazepine but increased tolerability and fewer drug 
interactions. The evidence is based on three randomised controlled trials including a total of 
130 participants, but only one has been published in full (with the rest in abstract form 
only).[31] [32]  
If a patient develops allergies to these drugs, international recommendations suggest the 
use of baclofen and lamotrigine.[31] [32] In a randomised controlled trial of 10 participants 
that lasted only seven days, Fromm and colleagues[45] showed a benefit of baclofen. 
However, owing to its limitations, the trial was excluded by a Cochrane systematic review 
[A: Edit correct?].[42] A crossover randomised controlled trial of 14 participants showed 
that lamotrigine in combination with carbamazepine or phenytoin was slightly more effective 
than placebo.[46] [41] These two drugs also have a high incidence of side effects, and 
lamotrigine must be escalated slowly to avoid skin rashes. A small randomised controlled 
trial combining gabapentin with regular ropivicane injections into trigger sites showed 
improved pain control and quality of life [A: Correct?], but these results have not been 
replicated.[47] A prospective, open label study of 53 patients followed up for one year reports 
the effectiveness of pregablin.[48] No trials of combination therapies such as those used in 
epilepsy have been conducted so far. 
What are the surgical options? 
Surgical options for trigeminal neuralgia fall into two categories: palliative destructive 
procedures (one of four procedures) and microvascular decompression. Microvascular 
decompression aims to decompress the trigeminal nerve, and deals with the cause of 
trigeminal neuralgia in the 95% of cases not caused by other lesional causes (fig 2[f2]).[12] 
Figure -  zakj014776.f2 
Fig 2 Compression of the trigeminal nerve in the posterior fossa and microvascular 
decompression. Intraoperative photographs taken during a microvascular decompression for 
left sided trigeminal neuralgia via a supralateral, cerebellar retrosigmoid approach. (A) Low 
power view showing severe proximal ventral trigeminal nerve compression of the trigeminal 
nerve (V) by the superior cerebellar artery (white arrow). (B) Higher power view showing the 
vascular interaction with the trigeminal nerve. (C) High power view of trigeminal nerve (V) 
after microvascular decompression, with superior cerebellar artery displaced rostrally (out of 
view) and held in position by shredded Teflon felt (black arrow). VII and VIII=cranial nerve 
VII and VIII complex  
[A: Please check edits to this paragraph are correct] Palliative destructive procedures 
involve partly controlled damage to the trigeminal nerve root with the aim to relieve pain, 
although there could be a risk of trigeminal numbness resulting from the planned nerve 
damage. They can be performed for all causes of trigeminal neuralgia, including non-vascular 
 decompression. Common procedures damage the nerve through heating (radiofrequency 
lesioning),[49] chemically (with a viscous glycerol called glycerol rhizolysis),[50] and 
mechanically (by crushing the nerve against surrounding bone and dural reflections called 
balloon compression).[51] All procedures involve a trans foramen ovale approach to the 
retrogasserian portion of the trigeminal nerve using a percutaneous needle. The latest 
technique is stereotactic radiosurgery, most commonly performed with the Gamma Knife, 
which damages the nerve root with a high and concentrated dose of radiation (fig 3[f3]).[52] 
There is very limited evidence for the use of peripheral treatments such as cryotherapy, 
neurectomy, or alcohol blocks.[53] 
Figure -  zakj014776.f3 
Fig 3 Targeting the trigeminal nerve with stereotactic radiosurgery using the Gamma Knife. 
Fine cut, 1 mm, axial T2 targeting images of a rhizotomy to the left trigeminal nerve root in a 
patient with trigeminal neuralgia. (A) Overview of the pons and the posterior fossa anatomy. 
(B-C) Sequential high magnification views of the trigeminal nerve root in relation to the dose 
plan. Inner circle=95% isodose line (76 Gy for an 80 Gy maximum treatment dose); outer 
circle=20% isodose line (16 Gy for an 80 Gy maximum treatment dose). In this case, two 
sector blocks were used to custom sculpt the radiation fall-off so that the surface of the brain 
stem received a dose no greater than 16 Gy 
[A: Paragraph ok as edited?] Only three randomised controlled trials [A: citations?] of 
reasonable quality have investigated surgical procedures although they do not include 
microvascular decompression.[53]  Furthermore, there is considerable variation in the quality 
of many cohort data studies. [54] According to large surgical series from multiple sites, 
microvascular decompression provides patients with about 80% chance of being pain-free 
without need for further treatment for trigeminal neuralgia, with a recurrence rate of about 
10% over 10-20 years.[12] [31] [32] [55-57] According to a systematic review for trigeminal 
neuralgia, the best surgical results in the short term (4 years) are achieved with 
microvascular decompression; the next best results come from the palliative destructive 
procedures, which have roughly equivalent results.[58] [59] A meta-analysis [A: Citation?] 
suggested that radiofrequency lesioning had a slight outcome advantage for patients with a 
higher incidence of treatment induced numbness[55]. Although all surgical procedures for 
trigeminal neuralgia have roughly equal chances of achieving pain relief without the need for 
drug treatment, microvascular decompression has a recurrence rate of about 4% per year 
which plateaus to about 1-2% per year by year six;[56] the palliative destructive procedures 
have a recurrence rate of about 50% after three to five years, increasing  [A: increasing?] 
linearly thereafter.[55] 
 [A: Paragraph ok as edited?] Even in experienced hands, microvascular decompression 
does carry the risk of a patient having to undergo general anaesthesia, a risk (<3%) of hearing 
loss, as well as the risks (<1%) common to elective open cranial microsurgery.[31] [32] [60] 
Percutaneous procedures (radiofrequency lesioning, glycerol rhizolysis, and balloon 
compression) all require brief periods of heavy sedation and are associated with autonomic 
responses of trigeminal-vagal nerve reflex, which may be important considerations for 
patients with significant cardiac disease. Large case series [A: Citation?] report that 
radiofrequency lesioning has the highest risk of facial numbness (often an intended 
consequence), and that balloon compression has a risk of temporary motor weakness in the 
trigeminal nerve.[59]  Stereotactic radiosurgery has the lowest risk of numbness, but does not 
take effect immediately, taking an average of four to six weeks for the onset of pain relief. 
No randomised clinical trials have compared the outcomes of surgical procedures for 
trigeminal neuralgia. But in two prospective cohort trials, microvascular decompression 
provided better results for pain relief as well as a lower recurrence rate than the Gamma 
Knife.[61] [62] 
What to do in a crisis? 
Patients who develop severe unremitting pain often attend emergency departments and are 
[A: usually? Normally?] usually given opioids, although there have been no reported trials 
investigating this. However, opioids anecdotally have no effect on this pain, and they have 
not been recommended by NICE guidelines.[44] Clinical experience shows that local 
anaesthesia injected into a trigger area can help pain relief. This technique was used in a 
randomised controlled trial combining ropivacaine and gabapentin, and even those patients 
who only had ropivacaine showed short term reduction in pain.[47] In a randomised 
controlled trial of 25 patients with second division pain, those given an 8% spray of lidocaine 
as opposed to saline had a statistically significant [A: statistically significant?] decrease in 
pain for a mean of four hours.[63]  
There is one report of three patients responding to intravenous infusion of 
fosphenytoin,[64] although this should only be performed under specialist supervision 
because hospital [A: OK?] admission and cardiac monitoring are required. This procedure 
can help to break the cycle and should be followed up an increase of oral drug treatments. 
Patients sometimes need to be admitted for rehydration and possible management of 
hyponatraemia if they have used high doses of antiepileptic drugs. Good oral hygiene needs 
to be maintained to prevent any additional dental pain, and a hygienist may be needed to 
 provide more detailed instructions. Patients in a crisis should be kept calm because they can 
feel overwhelmed by the pain and its continuation, which can induce more attacks.[65] 
What other support is available for patients with trigeminal neuralgia? 
In view of the rarity of trigeminal neuralgia [A: OK?], few general practitioners have 
experience of dealing with these patients, who can feel isolated and live in fear of developing 
a severe pain attack. Patient support groups have been shown to be helpful.[66] Meeting other 
healthcare professionals and fellow patients can help decision making about treatment 
choices, which is difficult because of the paucity of high quality evidence.[66] [67] 
 
Questions for future research 
What is the natural history of trigeminal neuralgia and are there associated risk factors? 
Is there a genetic basis? 
Are there objective biomarkers to confirm the clinical diagnosis, and can they be used to 
predict prognosis? 
What are the best care pathways to optimise quality of life and when should treatment change 
from medical to surgical management? 
What novel trial designs should be used to evaluate new drugs and different surgical 
procedures? 
How do we improve decision making for patients and ensure they give informed consent? 
 
 
Tips for non-specialists 
Rule out dental causes for the pain, but also remember that trigeminal neuralgia can present 
as toothache and result in unnecessary dental treatment 
Careful history taking should detect signs of symptomatic trigeminal neuralgia; if there are 
red flags, imaging should be used. Carbamazepine or oxcarbazepine are highly effective but 
need to be titrated up slowly because they cause significant side effects to the central nervous 
system 
Patients will have periods of remission, but it is important that they continue to have access to 
their drugs and learn to titrate the drugs themselves with the use of pain diaries 
Untreated or poorly treated trigeminal neuralgia could result in weight loss and depression, 
and can lead to suicide; thus prompt referral to multidisciplinary teams with an interest in this 
condition (neurosurgeons , neurologists pain specialist) is important 
Refer patients with uncontrolled symptoms for consideration of surgical procedures 
Opioids do not control this pain, and lidocaine injected into trigger points is much more 
effective in patients who develop severe unremitting pain 
 
 
 Additional educational resources 
Resources for healthcare professionals 
NICE clinical knowledge summaries (http://cks.nice.org.uk/trigeminal-neuralgia)—provides 
evidence based material on the diagnosis and management of trigeminal neuralgia in primary 
care guideline 173, November 2013. Free [A: Need for registration?] 
American Academy for Neurology guidelines (https://www.aan.com/Guidelines/)—search 
for trigeminal neuralgia [A: OK?] provides materials in various formats, with patient 
summaries. Free, no registration needed 
E-learning 20 minute session on trigeminal neuralgia hosted by the Cardiff University 
Community Centre (www.paincommunitycentre.org/article/diagnosis-and-treatment-
trigeminal-neuralgia)—prepared under the e-learning for healthcare scheme, it is targeted at 
primary care doctors and dentists, has short video clips on diagnosis, and a section on 
management and multiple choice questions. Free , no registration  [A: Free? Need for 
registration?] 
PIER trigeminal neuralgia module from the American College of Physicians 
(http://pier.acponline.org [A: OK to use following website instead? 
http://smartmedicine.acponline.org/content.aspx?gbosId=299])—comprehensive 
evidence based review of trigeminal neuralgia. Must be a member to access 
Professional sections on website for trigeminal neuralgia support groups (see below) 
Resources for patients 
Trigeminal Neuralgia Association UK (www.tna.org.uk)—also includes information for 
professionals, listing higher quality published articles and many links to other organisations 
for patients and professionals. Some information is freely available but members have access 
to a forum and more details 
Facial Pain Association (formerly the Trigeminal Neuralgia Association) (www.fpa-
support.org/ and www.endthepain.org)—the association caters for people with trigeminal 
neuropathic pain. Registration needed for free access 
Trigeminal Neuralgia Association Australia (www.tnaaustralia.org.au)—provides basic 
information on trigeminal neuralgia for free, but there is also a members’ area and regular e-
newsletter that provides research updates and details on each support group 
Trigeminal Neuralgia Association of Canada (www.tnac.org/)—provides basic information 
for free but also has a members’ area. This site provides clear pictures of surgical procedures 
(www.umanitoba.ca/cranial_nerves/trigeminal_neuralgia/manuscript/medications.html) 
Weigel G, Casey KE. Striking back: the trigeminal neuralgia and face pain handbook. 
Trigeminal Neuralgia Association, 2003—written by a sufferer with input from a 
neurosurgeon  it provides comprehensive material on trigeminal neuralgia which is jargon 
free [A: Please provide a short statement about what information this book provides for 
patients] 
Zakrzewska, JM. Insights facts and stories behind trigeminal neuralgia. Trigeminal Neuralgia 
Association , 2006—written by a doctor for sufferers it has contributions  from over a 
hundred sufferers and  provide a comprehensive review from both perspectives  [A: Please 
provide a short statement about what information this book provides for patients] 
Brain and Spine Foundation (www.brainandspine.org.uk/)—covers a wide range of 
neurological and neurosurgical conditions, and includes free download of booklet on head 
and face pain that provides details of trigeminal neuralgia and other related facial pain 
conditions 
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